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Introduction 
With new (and often expensive) medication to treat 
disease, drug expenditure continues to spiral 
upward. The specialty of dermatology, with its high-
priced topicals and biologics, has seen substantial 
increases in drug spending [1]. Resources are limited 
and someone has to decide which treatments will be 
covered and how they will be reimbursed. Some 
countries manage limited resources by making top-
down choices using cost-effectiveness and 
opportunity cost analyses, but in the United States 
our decentralized system is based on competition to 
control cost. Patients are, to a large extent, insulated 
from the cost of healthcare by their insurers. This 
leaves insurers in the position to negotiate with 
healthcare providers (hospitals, pharmaceutical 
companies, physicians) to provide patients quality 
healthcare at an affordable price. 
Step therapy 
One tool insurers use to control cost is step therapy 
(Table 1). Step therapy is a cost-control method that 
is being used by most commercial insurers and more 
recently, Medicare Part D to encourage the use of the 
most cost-effective treatments before more 
expensive options are attempted [2, 3]. Step therapy 
reduces drug costs by encouraging greater use of 
lower-cost options [4]. Insurers restricting access to 
expensive options put pressure on pharmaceutical 
companies to lower prices to make these options 
more cost-effective and more viable. This helps 
control the price of insurance for all people and 
leaves more resources available to fund access to 
other treatment needs [5]. 
Disease in individuals is complex with no one-size-
fits-all treatment. A rigid step therapy policy can be 
problematic when protocols are out of date or delay 
necessary treatment leading to unnecessary 
suffering, or worse, irreversible disease progression, 
Abstract 
Drug expenditure in the United States has continued 
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use of the most cost-effective treatments before 
more expensive options are attempted. However, a 
rigid step therapy policy can be problematic when 
protocols are out of date, or delay necessary 
treatment leading to unnecessary suffering, 
increased morbidity, and overall cost. To address 
some of these concerns, the proposed Safe Step Act 
(S. 2546 and H.R. 2279) attempts to create a 
requirement that insurers provide a transparent, 
expeditious exceptions process for step therapy 
protocols. Increased flexibility in this process will 
allow for the unique circumstances of individual 
patients and improve access to expensive drugs for 
special cases. However, this bill may be exploited, 
further weakening insurers’ ability to negotiate on 
cost. We should be cautious about measures that 
reduce the effectiveness of this tool, particularly if we, 
as a society, aim to expand access to basic care to all 
Americans. 
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increased morbidity, and overall cost. Step therapy 
increases the already heavy administrative burden at 
all levels of our system for the provider, staff, and 
insurer — which equates to further delay in 
treatment and increased costs [5]. 
Safe Step Act 
To address some of these downsides, a proposed 
amendment (Safe Step Act; S. 2546 and H.R. 2279) to 
the Employee Retirement Income Security Act of 
1974, is attempting to create a requirement that 
insurers provide a transparent, expeditious 
exceptions process for any medication step therapy 
protocol. Although many states have already passed 
similar legislation, this bill takes this regulation 
nationally. This bill requires decisions to be made 
within a reasonable time frame (72 hours). Increased 
flexibility in the step therapy process will allow for 
accounting for the unique circumstances of 
individual patients and more access to expensive 
drugs for special cases. The Safe Step Act makes 
changes providing a path to exception if treatment 
is contraindicated, is expected to be ineffective, will 
cause an adverse reaction, or will decrease the ability 
to perform daily activities, occupational 
responsibilities, or adhere to the treatment plan. An 
exception will be also be granted if a patient is 
already stable on a treatment already selected [6]. 
Limitations 
The Safe Step Act was created with the best of 
intentions and does standardize a step therapy 
exceptions process. However, these changes are 
vaguely written and depending on how they are 
interpreted, could be exploited, weakening insurers’ 
ability to negotiate on cost. One example is 
§716(b)(4)(B), which states that exemptions to step 
therapy may be made if the provider believes that a 
therapy will have poor adherence. Exemptions that 
could allow almost anyone to bypass cost control 
steps may unintentionally worsen the cost problem. 
Additionally, this bill fails to streamline the 
administrative burden of step therapy and will likely 
not reduce the paperwork or cost burden on 
providers. Specialized medicines like biologics are 
inherently expensive, even if insurers are successful 
at transparently reducing their unit cost. There is no 
free lunch and ultimately, if we want to maintain 
access to these medicines, we as a society must pay. 
Weakening step therapy will likely increase costs and 
may not much improve outcomes. 
We want the best for all patients, but resources are 
limited. To optimize care for the entire population, 
the use of the most cost-effective options has 
advantages. Physicians have to be focused on giving 
each patient the best available care, a goal that, at 
times, may conflict with the need to ration resources 
for the optimal benefit of all patients. In the United 
States, insurers have a role in making difficult cost-
conscious decisions. Whether insurers should be 
making these decisions is an important question, but 
someone must. Will the patients, the doctors, the 
payors, or the government take on the responsibility 
for considering costs? There is not an ideal answer. 
Step therapy is a mechanism by which insurers 
currently encourage cost-effective care. We should 
be cautious about measures that reduce the 
effectiveness of this tool, particularly if we, as a 
society, wish to expand some level of basic care to all 
Americans. 
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